[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100385638":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":11,"locations":27,"responsibleParty":41,"collaborators":11,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":11,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":11,"overallStatus":63,"whyStopped":64,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL",null,[13,14],"Drug: BMS-986235 (Treatment A)","Drug: Rifampin (Treatment B)",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":11},"DRUG","BMS-986235 (Treatment A)","Specified dose on specified days",[9],{"type":17,"name":22,"description":19,"armGroupLabels":23,"otherNames":11},"Rifampin (Treatment B)",[9],[25],{"name":5,"affiliation":5,"role":26},"STUDY_DIRECTOR",[28],{"facility":29,"status":11,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":11},"Local Institution","Salt Lake City","Utah","84124","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-111.89105,40.76078,{"lat":39,"lon":38},{"type":42,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100385638","phase-1-study-to-evaluate-the-effect-of-rifampin-on-the-drug-levels-in-blood-and-safety-of-bms-986235-in-healthy-participants-100385638",false,"NCT04301310","Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants","A Phase 1, Open-label Study to Evaluate the Effect of Rifampin on the Single Dose Pharmacokinetics, Safety, and Tolerability of BMS-986235 in Healthy Participants","For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Healthy participants, as determined by no clinically significant deviation from normal in physical examination, ECGs, and clinical laboratory determinations; no significant findings in medical history.\n* Body mass index of 18.0 kg\u002Fm2 to 30.0 kg\u002Fm2, inclusive, at screening\n* Males must agree to follow specific methods of contraception, if applicable\n\nExclusion Criteria:\n\n* Women of childbearing potential (WOCBP)\n* Known previous exposure to BMS-986235\n* History of any significant drug allergy\n\nOther protocol-defined inclusion\u002Fexclusion criteria apply",true,"ALL","18 Years","55 Years",{"count":55,"type":56},0,"ACTUAL","INTERVENTIONAL",[59],"PHASE1","The purpose of this study is to examine the effect of rifampin on the drug levels in blood and safety of BMS-986235, when taken by healthy participants.",[62],"Healthy Participants","WITHDRAWN","Business objectives have changed","2022-03-17",{"date":67,"type":56},"2022-03-31",{"date":69,"type":56},"2020-03-09",{"date":71,"type":56},"2020-03-16",{"name":5,"class":6},1]